XBiotech Inc.
XBiotech Inc. is a U.S.-based biopharmaceutical company focused on discovering and developing True Human™ monoclonal antibodies for a range of diseases. The company operates from its research and manufacturing campus in Austin, Texas, and combines antibody discovery, preclinical and clinical development, and in-house manufacturing capabilities.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaMonoclonal antibody drug candidates derived from human immune responses for inflammatory and infectious diseases.
Contract manufacturing of antibody drug product for third-party clinical use.
Trial operations and related support services provided under customer agreements.
Asiakkaat
XBiotech's primary customers are not traditional commercial buyers but pharmaceutical partners, regulators, and ultimately physicians and patients if its product candidates are approved. Historically, the company has also provided manufacturing and clinical trial support services to a large pharmaceutical customer under contract. Future demand depends on successful regulatory approval, reimbursement, and adoption in inflammatory and infectious disease markets.
Buy manufacturing and clinical support services for antibody programs and trial supply.
Would prescribe approved antibody therapies for inflammatory or infectious diseases.
End users of therapies targeting IL-1α, MRSA, shingles, influenza, and C. difficile.
Determine access and affordability for any approved commercial products.
May use the company's manufacturing and trial operations capabilities under contract.
Strategia
XBiotech's strategy centers on advancing its True Human™ antibody pipeline through preclinical and clinical development while retaining manufacturing control in-house. The company is also building the commercial and regulatory capabilities needed to move selected candidates into approval and eventual commercialization, including potential partnerships where appropriate.
Clinical and preclinical progress is the main path to future product revenue.
In-house production supports development speed, process control, and launch readiness.
Approved products require sales, marketing, distribution, and reimbursement access.
Maantiede
XBiotech is headquartered and operates its main research and manufacturing campus in Austin, Texas, while the company was originally incorporated in Canada. Its disclosures also reference Canadian banking activity and foreign exchange exposure between the U.S. dollar and Canadian dollar, indicating cross-border financial and operational links. Commercially, its future product approvals would likely involve both U.S. and foreign regulators such as the FDA and EMA.
Riskit
XBiotech faces the typical risks of a pre-commercial biopharmaceutical company: clinical failure, regulatory delay, and uncertainty around market acceptance and reimbursement. Company-specific risks also include dependence on a small number of manufacturing inputs, intellectual property protection, and the need to build commercial infrastructure if any product is approved.
- Clinical development failureVaikutus: KorkeaTodennäköisyys: Korkea
Drug candidates may not meet endpoints or show acceptable safety.
Kohdistuu: Pipeline programs in inflammatory and infectious diseases
- Regulatory approval riskVaikutus: KorkeaTodennäköisyys: Korkea
FDA and EMA review timelines are unpredictable and can require more studies.
Kohdistuu: All current and future product candidates
- Commercialization and reimbursement riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Approved products still need sales infrastructure and payer coverage.
Kohdistuu: Future marketed antibodies
- Manufacturing supply concentrationVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Key components come from limited vendors and alternate sources may be scarce.
Kohdistuu: Manufacturing operations
- Intellectual property riskVaikutus: KeskitasoTodennäköisyys: Matala
Patents may be challenged or insufficient to protect the platform.
Kohdistuu: True Human™ antibody technology and product candidates
Kirjanpito
Harkinnanvaraiset erätBlack-Scholes assumptions such as volatility and expected life affect expense recognition.
Vaikutus: Can materially change operating expense and net loss
Revenue depends on specific supply agreements and delivery timing.
Vaikutus: Creates lumpy revenue and comparability issues across periods
Future tax benefits depend on profitability and tax authority outcomes.
Vaikutus: Affects deferred tax assets and tax expense
Debt terms and interest recognition affect financing cash flows and expense.
Vaikutus: Influences interest expense and balance sheet classification
Canadian-dollar cash and transactions create FX gains or losses.
Vaikutus: Can add volatility to other income and net results
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Xencor Inc
XNCR · Pharmaceutical Preparations
Xilio Therapeutics, Inc.
XLO · Pharmaceutical Preparations
Xilio Therapeutics is a U.S.-based biotechnology company focused on developing tumor-activated immunotherapies for cancer.
Xenetic Biosciences, Inc.
XBIO · Pharmaceutical Preparations
CytomX Therapeutics, Inc.
CTMX · Pharmaceutical Preparations
CytomX Therapeutics is a clinical-stage biopharmaceutical company built around its PROBODY platform, which masks biologic drug activity until it reaches the tumor microenvironment.
X4 Pharmaceuticals, Inc
XFOR · Biological Products, (No Diagnostic Substances)
BioNTech SE
BNTX · Biological Products, (No Diagnostic Substances)
BioNTech SE is a biotechnology company focused on discovering and developing immunotherapies and other medicines, with a major commercial base in COVID-19 vaccines and a growing oncology pipeline.
Päivitetty: 24.9.2026